Sino Biological/Factor VII Protein, Human, Recombinant (His Tag)/1/11506-H08H
商品编号：
11506-H08H
品牌：
sinobiological
市场价：
¥0.00
美元价：
0.00
联系Q Q：
3392242852
电话号码：
4000-520-616
电子邮箱：
info@ebiomall.com
商品介绍
Factor VII Protein, Human, Recombinant (His Tag): Product Information
Purity
> 95 % as determined by SDS-PAGE
Endotoxin
< 1.0="" eu="" per="" μg="" of="" the="" protein="" as="" determined="" by="" the="" lal="">
Activity
Testing in progress
Protein Construction
A DNA sequence encoding the human F7 isoform B (P08709-2) (Met 1-Pro 444) was expressed, fused with a polyhistidine tag at the C-terminus.
Accession#
P08709-2
Expressed Host
HEK293 Cells
Species
Human
Predicted N Terminal
Ala 39
Molecule Mass
The secreted mature form of recombinant human F7 consists of 417 amino acids and predictes a molecular mass of 46.5 kDa. In SDS-PAGE under reducing conditions, the apparent molecular mass of rh F7 is approximately 50 kDa.
Formulation
Lyophilized from sterile PBS, pH 7.4Please contact us for any concerns or special requirements. Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.
Please refer to the specific buffer information in the hard copy of CoA.
Shipping
In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature.Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise.
Stability & Storage
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Reconstitution
A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.
Factor VII Protein, Human, Recombinant (His Tag): Images
Factor VII Protein, Human, Recombinant (His Tag): Synonyms
Coagulation factor 7 Protein, Human; Coagulation factor VII Protein, Human; SPCA Protein, Human
Factor VII Background Information
Coagulation factor VII, also known as Serum prothrombin conversion accelerator, Factor VII, F7 and FVII, is a member of the peptidase S1 family. Factor VII is one of the central proteins in the coagulation cascade. It is an enzyme of the serine protease class, and Factor VII (FVII) deficiency is the most frequent among rare congenital bleeding disorders. Factor VII contains two EGF-like domains, one Gla (gamma-carboxy-glutamate) domain and one peptidase S1 domain. The main role of factor VII is to initiate the process of coagulation in conjunction with tissue factor (TF). Tissue factor is found on the outside of blood vessels, normally not exposed to the blood stream. The action of the Factor VII is impeded by tissue factor pathway inhibitor (TFPI), which is released almost immediately after initiation of coagulation. Factor VII is vitamin K dependent and is produced in the liver. Upon vessel injury, tissue factor is exposed to the blood and circulating Factor VII. Once bound to TF, FVII is activated to FVIIa by different proteases, among which are thrombin (factor IIa), factor Xa, IXa, XIIa, and the FVIIa-TF complex itself. Recombinant activated factor VII (rFVIIa) is a haemostatic agent, which was originally developed for the treatment of haemophilia patients with inhibitors against factor FVIII or FIX. FVIIa binds specifically to endothelial protein C receptor (EPCR), a known cellular receptor for protein C and activated protein C, on the endothelium. rFVIIa is a novel hemostatic agent, originally developed for the treatment of hemorrhage in hemophiliacs with inhibitors, which has been successfully used recently in an increasing number of nonhemophilic bleeding conditions.
Full Name
coagulation factor VII (serum prothrombin conversion accelerator)
Research Areas
- Serine Proteases and Regulators
References
- Franchini M, et al. (2007) Potential role of recombinant activated factor VII for the treatment of severe bleeding associated with disseminated intravascular coagulation: a systematic review. Blood Coagul Fibrinolysis. 18(7): 589-93.
- Lapecorella M, et al. (2008) Factor VII deficiency: defining the clinical picture and optimizing therapeutic options. Haemophilia. 14(6): 1170-5.
- Grottke O, et al. (2010) Activated recombinant factor VII (rFVIIa). Best Pract Res Clin Anaesthesiol. 24(1): 95-106.
Mouse Factor VII Proteins
- Factor VII Protein, Mouse, Recombinant (His Tag)50034-M08S
- Novel Antibody against a Glutamic Acid-Rich Human Fibrinogen-Like Protein 2-Derived Peptide near Ser91 Inhibits hfgl2 Prothrombinase ActivityAuthorLi, WZ;Wang, J;Long, R;Su, GH;Bukhory, DK;Dai, J;Jin, N;Huang, SY;Jia, P;Li, T;Fan, C;Liu, K;Wang, Z;Year2014JournalPLoS ONEApplicationWBPubMed ID: 24728278FoldedExpand
If you couldn"t find the specific citation, you can:
- Find All Citations
- Submit a CitationGet a Publication Reward
- Leave Us a Message
E.coli protein expression service
Mammalian transient protein expression service
Baculovirus-insect expression service
Stable cell line development service (CHO / HEK293)
品牌介绍
北京义翘神州科技股份有限公司（Sino Biological Inc.）是一家从事生物试剂研发、生产、销售并提供技术服务的生物科技公司，主要业务包括重组蛋白、抗体、基因和培养基等产品，以及重组蛋白、抗体的开发和生物分析检测等服务。义翘神州为全球的药品研发企业和生命科学研究机构提供高质量的生物试剂产品和高水平的技术服务。公司目前生产和销售的现货产品种类超过 4.6 万种，其中重组蛋白约 6,000 种，包括超过 3,800 种人源细胞表达重组蛋白产品，能够全面满足客户对于最接近人体天然蛋白结构和性质的重组蛋白需求；公司还能提供约 12,000 种抗体，其中单克隆抗体数量约 4,600 种，能够覆盖生命科学研究的多个领域，为分子生物学、细胞生物学、免疫学、发育生物学、干细胞研究等基础科研方向和创新药物研发提供「一站式」生物试剂产品和技术服务。义翘神州的客户涵盖大学、科研院所、医药研发企业等国内外各类生物研发单位。目前公司已经在美国、欧洲建立了子公司，已成为生物试剂行业国内领先的科技公司之一。
联络我们
